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Abstract
Background: The COVID-19 pandemic has affected the world deeply, with more than 14,000,000 people infected
and nearly 600,000 deaths. This review aimed to summarize the epidemiologic traits, clinical spectrum, CT results
and laboratory findings of the COVID-19 pandemic.
Methods: We scoped for relevant literatures published during 1st December 2019 to 16th July 2020 based on
three databases using English and Chinese languages. We reviewed and analyzed the relevant outcomes.
Results: The COVID-19 pandemic was found to have a higher transmission rate compared to SARS and MERS and
involved 4 stages of evolution. The basic reproduction number (R0) is 3.32 (95% CI:3.24–3.39), the incubation period
was 5.24 days (95% CI:3.97–6.50, 5 studies) on average, and the average time for symptoms onset varied by
countries. Common clinical spectrums identified included fever (38.1–39.0 °C), cough and fatigue, with Acute
Respiratory Distress Syndrome (ARDS) being the most common complication reported. Body temperatures above
39.0 °C, dyspnea, and anorexia were more common symptoms in severe patients. Aged over 65 years old, having
co-morbidities, and developing complications were the commonest high-risk factors associated with severe
conditions. Leucopenia and lymphopenia were the most common signs of infection while liver and kidney damage
were rare but may cause bad outcomes for patients. The bilateral, multifocal Ground-Glass Opacification (GGO) on
peripheral, and the consolidative pulmonary opacity were the most frequent CT results and the tendency of
mortality rates differed by region.
Conclusions: We provided a bird’s-eye view of the COVID-19 during the current pandemic, which will help better
understanding the key traits of the disease. The findings could be used for disease’s future research, control and
prevention.
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Background
The emergence of COVID-19 has made it the first infec-
tious disease pandemic in the twenty-first century. As of
20th July 2020, a total of 14,348,858 people got infected,
and 603,691 were confirmed dead in 213 countries, terri-
tories, and areas globally [1]. While more than 30 coun-
tries had issued the highest level of response, the SARS-
CoV-2 (pathogen of COVID-19) continues to spread in
different regions around the world [2]. However, the key
information on the virus epidemiology, clinical spectrum,
and on the pathogen was delayed in response during the
early outbreaks in many countries. To fill the research
gaps mentioned above, this review article systematically
summarizes global findings on the natural history, clinical
spectrum, transmission patterns, laboratory findings, CT
results, and risk factors of the COVID-19.
Methods
Search methods for identification of studies
We searched for publications in epidemiology and clinic
domains of the COVID-19 broadly. The databases we
searched were: CHKD v3.1 of the CNKI [in Chinese],
PubMed, and medRxiv, by using such search terms as
‘COVID-19, SARS-CoV-2, and 2019 nCoV’ (See Add-
itional file 1). The publication date was restricted from
1st Dec 2019 to 16th Jul 2020. Both English and Chinese
were applied for the search. Only the full-text available
human studies were eligible for selection. Like the real-
time data, other data were obtained from health depart-
ments of multiple countries, global NGOs, and reputable
media sources.
Data collection and analysis
Selection of studies
The searched records were firstly screened by reading
titles and abstracts. Then, the rest records were
screened again by full-text reading. If there were dis-
agreements initially, the records then submitted to
the whole team for further discussions. Besides, a
PRISMA diagram was conducted to illustrate the en-
tire flows of the review (Fig. 1).
Fig. 1 PRISM flow diagram
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Data extraction, management, and dealing with missing
data
The data for the quantitative analysis was extracted and
managed by using Microsoft Excel 2010 (Microsoft©, Red-
mond, WA, USA). The meta-analysis was performed by
the R version 4.02 and RStudio (2020) [3]. The Cochrane
Handbook for Systematic Reviews of Interventions sug-
gested review authors collect missing data from investiga-
tors. Considered that using the imputation method to
tackle the missing data problem could not reduce bias, we
only analyse data available to us if we could not collect the
missing data from the investigators [4].
Assessment of heterogeneity and reporting biases, and data
synthesis
The heterogeneity of the included studies was assessed
by using I2. The P-value was generated by Wald-type
test and Likelihood-Ratio test. The overlapping Confi-
dence Intervals (CIs) were displayed by the forest plots
(See Additional file 4). We categorized and combined
the data about epidemiologic traits, clinical spectrums,
laboratory, and imageology findings in a narrative. Then
we further analyze the data about common symptoms,
reproduction number, and incubation period through
meta-analysis. The quantitative outcomes were com-
bined with the narrative of epidemiological and clinical
findings.
Results
We collected 11,366 records after removing duplications.
After three batches of screening, 127 records were in-
cluded in this review (See screening details in Fig. 1).
Epidemiology
Demographic characteristics
In a China based study involving 55,924 COVID-19 pa-
tients, the majority of patients were aged 30–69 (77.8%)
with only 2.4% of the patients being 18 years and below.
The median age of the patients was 51 (ranged 2 days-
100 years old) [5]. Similarly, in the United States, more
than half of patients were aged between 20 and 64 years
(65%), with only 5% of patients being under 19 years old.
Older aged patients were more prone to getting infected
compared to the young [6]. By gender, the male to fe-
male ratio of confirmed cases was 1.06:1.00 in China [7].
However, in South Korea and Iceland, the male popula-
tion had a higher incidence rate than the female popula-
tion [8, 9]. Males had twice the secondary attack rate
than females [10].
Transmission stages
The COVID-19 transmission stages could be categorized
into four temporal stages according to the chronological
order of case reports. The first stage: people with
exposure histories to Huanan Seafood Market (HSM) got
infected [11]. Forty-one patients were found to be having
SARS-like symptoms in December 2019, and the HSM
was believed to be one of the origins of the virus. How-
ever, 13 of the 41 patients reported no prior exposure to
the HSM thus indicating that the origin of the virus
needed further investigation [12]. The second temporal
stage is the transition from community transmissions to
the outbreak in Wuhan [11]. The virus was mainly spread
to multiple communities directly and indirectly by people
with HSM exposure histories. The interpersonal transmis-
sions and clustered transmissions formed community
transmissions [11]. An earlier study showed that the pro-
portion of patients with HSM exposure histories de-
creased from 55 to 8.6% within 22 days, indicating when
people who did not have exposure histories to the HSM
became infected [13, 14]. The third stage: the epidemic in
China. At this stage, transmissions began to expand to
communities outside Wuhan and the Hubei province as a
whole [11]. On 26th Jan 2020, a study involving 62
COVID-19 patients outside Wuhan found that all the pa-
tients had been exposed to Wuhan, which demonstrated
an established local transmission outside Wuhan [15].
The fourth temporal stage is the global pandemic. On
13th Jan 2020, the first case outside China was reported in
Thailand [2]. On 30th Jan 2020, the WHO declared a Pub-
lic Health Emergency of International Concern (PHEIC)
[2]. It subsequently took about 51 days for transmission to
escalate from the first reported case to the 10,000th re-
ported case outside China. Globally, it took 16 days for the
number of reported cases to increase from 10,000th cases
to 100,000th cases, 21 days from 100,000th cases to 500,
000th cases, only 6 days from 500,000th cases to 1,000,
000th cases and 13 days from 1,000,000th cases to 2,000,
000th cases [2].
Transmission routes
The main transmission route of this virus was by
human-to-human spread, since only 1.18% patients
among 1099 confirmed patients had history of direct
contact with wild animals [16]. The vital transmission
routes were through respiratory droplets and contact
transmissions. There remains the possibility of aerosol
transmission when exposed to high concentrations of
aerosols for a long time in a relatively closed environ-
ment [17]. Mother-to-child transmission has been con-
firmed, whiles fecal-oral transmission was also
considered possible but lacked direct evidence until now
[18, 19]. Other suspected routes of transmission still
needed further clarification.
Transmission patterns
Community transmission, nosocomial transmission,
household transmission, and transmission in closed
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environments were four typical transmission patterns of
the COVID-19.
Firstly, community transmission was considered to be
an important pattern in COVID-19 spread [5]. In the
Netherlands, community transmissions were found in
the Noord-Brabant regions [20, 21]. In North America,
community transmissions were reported in Winnipeg,
Canada, and Eastern Idaho, United States [22, 23].
Secondly, the potential risk of transmission among
medical personnel and through medical facilities was
deemed high and thus extreme attention should be paid.
Transmissions between patients and health workers were
in higher proportions during the SARS outbreak, while
transmission through medical facilities was higher in
proportion during the MERS outbreak [24]. In Wuhan,
the proportion of severely infected medical workers was
higher than the national average [7]. In Italy, 2629 health
workers were reported infected with the COVID-19 be-
fore 18th March and accounted for 8.3% of the total
number of cases nationwide. The number however in-
creased to 8358 by 30th March and represented 9% of
the country’s total number of cases [25, 26]. In Spain,
the number of diagnosed cases among medical workers
increased to 5969 within 6 days and more than 12% of
the country’s confirmed cases remained among medical
workers until March 30th [25]. Update from another
source reported an increase in the number of cases from
12 to 14% among Spain healthcare workers by 31st
March and this was attributed to lack of medical sup-
plies, such as masks and gowns. Other reasons account-
ing for these high infection rates among medical
personnel varied according to different country’s circum-
stances. An Italy study pointed out hospitals as a poten-
tial hotspot for infection. Facilities and medical
personnel turned into untested vectors and patients [27,
28]. In the US for example, the reasons that turned hos-
pitals into infection hotspots included the overload of
COVID-19 patients and inappropriate management
against the pandemic in hospitals [29]. Similar to the
US, 200 medical workers got infected in a county hos-
pital in Romania due to inadequate hospital manage-
ment. In Egypt, a serious wave of emigration by
physicians for years led to patient overload for remaining
medical workers and placed them at higher risk of infec-
tion through continuous exposure. The emigration wave
was purportedly caused by low salary, undesirable work-
ing conditions, lack of legal protection, and shortage of
medical supplies and equipment [30].
Thirdly, household transmission contributed to cluster
infections and was the major transmission pattern ob-
served in China. For instance, among 1836 reported
cases in Guangdong and Sichuan Provinces, most cluster
infections occurred in families (78–85%) [5]. The WHO
in this regard issued a statement that household
transmission highly occurred among medical workers’
families than health facility infection in China. House-
hold transmission was also a significant pattern observed
in South Korea and the US [2, 29]. The European Centre
for Disease Prevention and Control (ECDC) had pro-
vided guidance for the control of household transmis-
sion in European countries [5, 31]. What made
household transmission worse was that some groups
(age < 18 and > 65) had high risk got infection within
households than the general population [32]. So, chil-
dren and elderly living with medical workers at a higher
risk of getting than other populations.
Fourthly, transmissions in a closed environment be-
sides the home should also be of a keen focus on the
prevention and control of this outbreak. A Japanese
health department reported that a closed environment
could promote super-spreading events because the
transmission of the SARS-CoV-2 in a closed environ-
ment was the same as large-scale transmission, such as
the ski chalet-cluster infection in France and the
church-hospital infection clusters in South Korea [33].
For example, outbreaks of the COVID-19 were observed
in multiple prisons in China, the UK, and the US [7, 34,
35]. Cluster infections also happened on cruise ships,
such as the Diamond Princess, Grand Princess, Golden
Princess, Ruby Princess, Phoenix Reisen, MS Wester-
dam, and Punta Arenas [36]. Further studies are how-
ever required to identify and assess other potential
transmission patterns for further prevention, especially
since some cases were asymptomatic [37, 38]. In
addition, patients who were considered cured and no
longer needed quarantine still tested RT-PCR positive
after 5 to 13 days [39].
Nature history
We systematically used the data of the incubation period
and the reproduction numbers for meta-analysis (see de-
tails of selected studies on Additional file 2). The result
suggested that the mean incubation period was 5.24 days
(95% CI:3.97–6.50, 5 studies), and ranged from 3 to 7.4
days [40–44]. However, the incubation period in some
special cases could be as long as 24 days [16]. The result
also illustrated that the basic reproduction number (R0)
of SARS-CoV-2 was 3.32 (95% CI:3.24–3.39, 14 studies)
and varied between 0.6–6.47 [37, 42–53]. This finding
suggested that the transmission ability of SARS-CoV-2
was stronger than SARS (3) and MERS (≤1) [54, 55].
Moreover, the median time from the first symptom to
first hospital admission was 7 days with the median dur-
ation from illness development to severe symptoms de-
velopment being: 5–8 days for dyspnea, 8–9 days for
ARDS, 10.5 days for mechanical ventilation and ICU ad-
mission [6, 18]. For COVID-19 related deaths, the dur-
ation from the onset of symptoms to death averaged 9
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days in China 5 and in Italy (median) [56], and 10 days
in South Korea (median) [9].
Mortality and fatality
By 14th July 2020, 21 nations had reported over 100,000
COVID-19 cases in each of the countries, together con-
tributed to 81.4% of the confirmed cases and 81.3% of
death in the world1. The world case fatality rate (CFR)
was 4.4% on 14th July; however, it was apparently differ-
ent by country. One third of these 21 countries had a
CFR of over 4.4%. France (17.4%), United Kingdom
(15.5%), Italy (14.4%), and Mexico (11.6%) were the top
four countries with over 10% CFR while Qatar (0.1%)
and Saudi Arabia (1.0%) were the two countries with no
more than 1% CFR. Most countries experienced an in-
crease of CFR at first, and the number was then gradually
becoming stable during the disease outbreak (Fig. 2).
However, the CFR was high in Iran (13.7% on 27th Febru-
ary) and the United States (7.2% on 4th March) at first, ex-
perienced a sharp decrease to 2.5% on 8th March and
1.1% on 20th March, and rebounded to 5.0 and 4.0% on
14th July, respectively. Bangladesh was the only country
that had high CFR of around 10% at the beginning and
then continuously decreased until 1.3% on 14th July. As
the pandemic outbreak continued, more surveillance is
needed for the CFR of COVID-19 [57].
The mortality is higher among elderly, patients requir-
ing intensive care unit admission and male. However,
mortality rate among younger age group and patients
with mildly disease is less. The US’s data indicated that
patients younger than 19 had milder COVID-19 illness,
with almost no hospitalizations or deaths reported [6].
Based on a worldwide data, the elderly (aged over 60)
were at a high risk of developing into death [5, 6, 9, 56].
The mortality in ICU was extremely higher than Non-
ICU patients, varied from 26 to 78% [58–61].
About the gender ratio, there is a seemingly unques-
tionable pattern that COVID-19 killed more men than
women [62]. Unlike the less report in the research from
China, South Korea or other Asia areas, the reports from
Europe and American reflect the male gender is the risk
factor for heavy illness. To figure out the general situ-
ation around the world, here we analyzed the data from
53 countries, compiled centrally and individually verified
by authors against country-specific reports [63], shown
that the case-fatality rate among male is about 35%
higher than female (IR = 1.35, 95% Confidence interval:
1.35–1.35) (Table 1). The sex-disparity is consistent
across age groups and regions. For example, the inci-
dence rate ratios between male and female were 1.05
(95% CI: 1.05,1.05), 1.46 (95%vCI: 1.46,1.46), 1.46 (95%
CI: 1.46, 1.46), 1.61 (95% CI: 1.61,1.61) and 1.64 (95%
CI: 1.64, 1.64) among COVID-19 cases in Asia, Africa,
North America, South America, and Europe, respectively
(Table 1). By age groups, COVID-19 cases aged below
60 years old (IR = 2.74 95% CI: 2.66–2.82), have wider
sex-disparity than those aged above 60 years old (IR =
1.83, 95% CI: 1.82–1.83), while deaths among cases
younger than 40 years old are very rare.
Clinical spectrum
Common symptoms
Based on the data collected from selected articles [12,
15, 16, 58, 64–92] (details of selected articles were put in
the Additional file 3), we conducted the meta-analysis
using a random-effects model to identify the clinical fea-
ture of COVID-19. Fever (76.70, 95% CI: 64.86–85.44%)
and cough (67.76, 95% CI: 60.06–74.61%) were the most
Fig. 2 Case fatality rate of countries reported over 20,000 cases, 2020*. *Data was collected until 14 July 2020 (i.e. the 196th day of year 2020).
The CFR of a country was not included on those dates when the country reported less than 100 cases, with the consideration that the CFR may
not be reliable if the size of infected population was small
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common symptoms. Other common symptoms in-
cluded: olfactory (44.40%), gustatory (38.16%), dyspnea
(37.49%), fatigue (29.93%), sputum production (17.85%),
sore throat (16.17%) and headache (15.49%). All the
other data showed in Table 2. Besides, studies pointed
out that most patients had more than one symptom [68,
70, 71]. Additionally, there were 20.9% of patients with-
out viral pneumonia symptoms [16], which was opposite
to previous studies [69, 70]. The asymptomatic cases
varied from 21.9–49.5% [66, 68, 93, 94].
The top 3 common symptoms among mild and se-
vere patients are summarized and displayed in a fig-
ure (Fig. 3) [12, 16, 61, 70, 95–98]. Fever was found
to be the most common symptom in all patients. In a
study, 43.8% of patients had fever initially and the propor-
tion increased to 87.9% following hospitalization [16]. The
body temperatures of 44–47.1% of patients ranged be-
tween 38.1–39.0 °C. The higher body temperatures
(above 39.0 °C), dyspnea and anorexia were more fre-
quent among patients in severe conditions [16, 64,
98]. Cough and fatigue were more widely reported
among mild and severe patients. Additionally, another
study reported that dyspnea (76%) was the most com-
mon symptom among severe patients in the United
States [99]. The proportion of patients who needed
ICU care varied based on the local pandemic circum-
stances. For example, the WHO speculated that
around 13.8% of patients were in severe conditions in
China [5]. However, 23–32% of patients needed ICU
care in Wuhan [64, 69, 70].
Common complications
Currently documented COVID-19 related complica-
tions include ARDS, arrhythmia, Septic shock, acute
cardiac injury, myocarditis, acute coronary syndrome,
cardiomyopathy, acute respiratory injury, and acute
renal injury, etc. [58, 64, 67, 69, 70, 100]. The ARDS
was the most common complication, among both
mild and severe patients [58, 64, 67, 69, 70]. Most
ICU patients had a higher risk of developing ARDS
and having complications [12, 70]. The progress of
some patients with ARDS to septic shock was fast
and quickly evolved into multiple organ failure
finally [69].
Laboratory findings and CT scans
Laboratory findings
Among COVID – 19 patients, a decrease in leukocytes
such as eosinophil and lymphocyte were commonly re-
ported. This might be because the cytokine storm caused
Table 1 Gender based fatality rate ratio among COVID-19 cases
in different region of the world (By July 9th, 2020)
Variables Sex Fatality rate ratio (95% CI)
Region Global Female 1.00
Male 1.35 (1.35, 1.35)
Asia Female 1.00
Male 1.05 (1.05,1.05)
Africa Female 1.00
Male 1.46 (1.46,1.46)
North America Female 1.00
Male 1.46 (1.46,1.46)
South America Female 1.00
Male 1.61 (1.61,1.61)
Europe Female 1.00
Male 1.64 (1.64, 1.64)
Age < 60 Female 1.00
Male 2.74 (2.66,2.82)
60–69 Female 1.00
Male 2.36 (2.33,2.40)
70–79 Female 1.00
Male 1.76 (1.75,1.76)
80 and above Female 1.00
Male 1.91 (1.91,1.91)
60 and above Female 1.00
Male 1.83 (1.82,1.83)
Table 2 Meta analyzed results of COVID-19 common clinical symptoms (By July 16th, 2020)
Proportions 95% Confidence interval Heterogeneity test, I2 Heterogeneity test, P Value Number of studies
Fever 76.70% 64.86–85.44% 99.7% 0 21
Cough 67.76% 60.06–74.61% 99.2% < 0.0001 21
Olfactory 40.80% 20.31–65.08% 99.4% 0 14
Gustatory 34.52% 18.83–54.50% 98.9% < 0.0001 13
Dyspnea 37.49% 26.20–50.34% 99.6% 0 19
Fatigue 29.93% 14.22–52.39% 99.7% < 0.0001 11
Sputum production 17.85% 9.25–31.65% 99.1% < 0.0001 10
Sore throat 16.17% 10.05–24.98% 96.9% < 0.0001 9
Headache 15.49% 7.83–28.33% 98.7% < 0.0001 12
Xie et al. BMC Infectious Diseases          (2020) 20:640 Page 6 of 12
by the novel virus changes the peripheral of white blood
cells and immune cells [12, 13, 15, 16, 69, 70]. Severe
lymphopenia was also common among the dead pa-
tients [12, 61]. Myocardial zymogram abnormality was
found in many patients. For instance, 76% of patients
had an increase in lactate dehydrogenase, while 13%
of patients had increases in creatine kinase [69]. The
level of C-reactive protein was important to evaluate
the infection [16]. Most patients were found to have
a higher level of C- reactive protein (86%) and serum
ferritin (63%) compared to the normal range [69].
The biomarkers related to liver and renal damage
were found to be abnormal among COVID-19 pa-
tients. The abnormality of liver-related biomarkers
was not widespread but yet still common in severe
cases [12, 15, 16, 101]. Besides, although only 7% of
patients showed renal biomarker abnormalities, renal
damage might contribute to the final multi-organ fail-
ure and death outcome [102, 103].
The ICU patients showed higher levels of white blood
cells, neutrophil counts, D-dimer, creatine kinase, and
creatine with longer prothrombin times [12, 16, 70].
Compared to patients who survived, the patients who
died had higher levels of D-dimer, high-sensitivity car-
diac troponin I, serum ferritin, lactate dehydrogenase,
IL-6, blood urea, creatinine, white blood cell counts and
neutrophil counts. Severe lymphopenia was also com-
mon among dead patients [12, 61].
Computed tomography scan (CT scan) features
The Computed Tomography Scan (CT scan) was widely
used for disease diagnosis, prognosis, and management
during the COVID-19 [104]. The CT was found more
sensitive for identifying SARS-CoV-2 patients than the
RT-PCR assay (98% vs. 71%) in a study [105]. The CT
evidence for confirming the highly suspected patients’
positive may precede the RT-PCR results [106, 107].
Most patients had GGO and the bilateral lung involve-
ment [12, 69, 108–110]. One study found that bilateral lung
involvement was more frequently shown in the intermedi-
ate course and late course, compared to the earlier clinical
course [107]. The clinical course could be divided into four
stages based on CT scan findings [110]. In the first stage
(Pre-symptom), GGO, unilateral and multifocal were ob-
served among most patients in this stage [107, 110]. In the
second stage (symptoms ≤1week), lesions soon developed
into bilateral and diffused except for GGO. This stage was
considered a period from transition to consolidation. A
mixed pattern of transition and consolidation develops dur-
ing this stage. In the third stage (symptoms 1–2 weeks), the
GGO was still common and the consolidation pattern
showed. Findings indicated an interstitial change, which
was considered as the development of fibrosis. In the fourth
stage (symptom 2–3 weeks), consolidation and mixed pat-
terns were more common, and the GGO started to shrink
[110], the consolidation was gradually absorbed among pa-
tients who recovered at last [111].
Fig. 3 Comparison of top 3 symptoms among mild and severe patients with COVID-19, 2020*. *The X-axis means the number of symptoms
reported by how many studies. The Y-axis means symptoms’ ranking in mild and severe patients. In this circumstance, rank means the order
judged by the frequency of the symptoms reported among studies
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Among ICU patients, the bilateral multiple lobular and
sub segmental areas of consolidation were considered
typical findings [12]. Patients in severe condition showed
diffuse lesions, with density increasing in both lungs. CT
scans showed ‘white lung’ appearances, indicating the
serious influence the infection has on patients’ lung
functions [112].
Risk factors
Being old (≥65 years old), male sex, having a higher BMI
value (> 35 Kg/m2), having co-morbidities (e.g. hyperten-
sion, diabetes, cardiovascular and cerebrovascular dis-
eases, etc.), and developing complications were vital risk
factors for patients to develop severe conditions [59, 70,
78, 95, 96, 113, 114]. The cytokine storm, raised inflam-
matory markers, elevated cardiac troponins, the require-
ment of mechanical ventilation, and the requirement of
intensive care unit stay predict the bad outcome of ad-
mission patients [61].
Findings from multiple studies showed that patients
who are more than 65 years of age, with co-morbidities
such as diabetes and heart diseases had a high mortality
rate [61, 95, 115–117]. Late hospitalization and bacterial
infections were also considered high risk factors for dis-
ease progression [69, 96, 116]. Smoking history could be
a potential risk factor for developing severe conditions
[69, 96]. People with underlying disorders were consid-
ered to be at a high risk of getting infected [5].
Discussion
Research gaps
Our review identified several research gaps. Firstly, large
amounts of data from African were missing from this re-
view. As the number of people in African suffering from
malnutrition, anemia, malaria, HIV/AIDs and tubercu-
losis is high, a large “low immunity population” has been
created which has made the control and prevention of
COVID-19 in the region a challenge. The situation could
be worsened by the limited health resources region [118]
and hence, more African focused research is required to
support Africa in fighting the epidemic.
Secondly, the proportion of asymptomatic patients is
large but the current transmission ability by asymptom-
atic patients might be weak. However, further explor-
ation of risks posed by the group is needed as limited
studies exist on the subject matter [119]. Meanwhile,
data on the distribution of asymptomatic patients in
large-scale community groups is also lacking, prompting
the need for large scale of active screening and testing to
help identify them [93, 120]. This approach is however
difficult and expensive for most countries to undertake
as accurate strategies to identify asymptomatic currently
are non-existent. Further research focus on asymptom-
atic patients is needed.
Third, a ‘super-spreader’ was defined as infected indi-
viduals who infected numerous others during the SARS
outbreak. For example, a nephrotic hospitalized patient
who infected 22 people was classified as a ‘super-
spreader’ during the SARS in China. 19 in those 22 pa-
tients were medical workers who came in contact with
the ‘super-spreader’. The incidence rate among the med-
ical workers was 59.38% (19/32) in the nephrotic depart-
ment [121]. In the COVID-19 era, the emergence of
‘super-spreaders’ were found in multiple places world-
wide. A Saudi Arabian study linked the concept of
‘super-spreaders’ to ‘super spreading’ events noting that
‘super-spreaders’ might cause unexpected transmissions
during the pilgrimage [122], as huge numbers of people
gather. Reasons causing the super-spreading events
might include: immune suppression, increased disease
severity and viral load, asymptomatic individuals, and
extensive social interactions [123]. However, the charac-
teristics and features of how an individual becomes a
super-spreader are still not clear [124]. Summarizing the
features of the ‘super spreader’ concept, as well as their
characteristics and role in transmissions, are needed in
future disease control [125].
Fourth, it has been reported that some cured patients
COVID-19 retested positive by PCR after being dis-
charged and quarantined at home in multiple places [39,
126]. The reason for this phenomenon is still unclear
and hence further investigations are required for future
pandemic control [127].
Limitations
There existed some limitations in this review. Firstly,
this review was based on English and Chinese resources
only. As the COVID-19 transformed from a regional
outbreak to a global pandemic, comprehensive collection
of the related information worldwide is needed. Sec-
ondly, the clinical spectrum presented in this review is
based on general population only, and thus a further
subgroup analyzes in future may help to figure out more
on the entire picture of the COVID-19. For instance, al-
though Kawasaki disease was found in children in the
UK and Europe countries, other places did not report
the gathering Kawasaki disease cases [128].
Conclusions
The COVID-19 had a stronger transmission ability than
SARS and MERS, timely intervention should be con-
ducted to reduce the spread of the disease. The common
symptoms included in this study could assist in identify-
ing the potential patients. The summary of the common
complications, lab findings, CT features and risk factors
could help medical personnel better manage patients
who may develop into severe conditions or death.
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